|Bid||199.06 x 100|
|Ask||199.14 x 100|
|Day's Range||197.30 - 200.15|
|52 Week Range||184.50 - 256.80|
|PE Ratio (TTM)||6.09|
|Dividend & Yield||2.80 (1.36%)|
|1y Target Est||N/A|
Cramer says he'll buy more shares of the lackluster drugmaker for his charitable trust if the price drops below $200.
Allergan had made a widely-criticized agreement with an American Indian tribe to defend a key product. This lawsuit could render it all moot.
A U.S. District Court ruled patents for one of Allergan’s best-selling drugs are invalid, potentially opening the door for generic competition.
With its stock price in a free fall after a federal judge invalidated patents covering the dry eye drug Restasis, what’s next for Allergan (AGN). ... a generic version of Restasis has not yet been approved and even if a generic were approved within that time frame, a launch prior to the conclusion of that appeal would be considered ''at-risk''. Today’s court ruling is the latest development in the legal dispute pitting Allergan against a group of generic drug makers led by Teva Pharmaceutical Industries (TEVA) and Mylan (MYL).
Shares of pharmaceutical company Allergan Plc dropped on Monday after a ruling by a U.S. judge invalidated patents on its dry eye medicine Restasis on the grounds that the patents cover obvious ideas. Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers led by Mylan NV and Teva Pharmaceutical Industries Ltd. The ruling could enable the generic drug companies to sell their own versions of Restasis, which generated around $1.5 billion in sales for Allergan last year and accounted for more than 10 percent of the company's revenue.
Allergan PLC shares dropped 5% in extremely heavy afternoon trade Monday after a Texas district court judge ruled against the company in a patent lawsuit regarding the company's key billion-dollar dry ...
Generic-drug company Mylan has fired back at rival Allergan’s attempt to shield its top-selling eye medication from competition by transferring the patents to an Indian tribe.
Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.
Looking for some investments in the healthcare sector that aren't priced at a high premium? Allergan, Gilead Sciences, and DaVita are an excellent place to start.
Bigwigs of late have been investing a substantial portion of their R&D sources for the treatment of Non-Alcoholic Steatohepatitis (NASH).
Allergan Plc said on Thursday it reached a settlement with InnoPharma Inc, one of the four generic drugmakers challenging the patents for its dry eye medication Restasis in federal court. Mylan NV, Teva Pharmaceutical Industries Ltd and Akorn Inc are still contesting those patents in U.S. District Court in Marshall, Texas.
Ardelyx's (ARDX) tenapanor reduces abdominal pain and improves bowel movements in a phase III study evaluating the drug in irritable bowel syndrome with constipation.
Allergan plc (AGN) announced that the FDA has accepted the new drug application (NDA) for ulipristal acetate, for the treatment of abnormal uterine bleeding in women with uterine fibroids.
The group is the latest to call on lawmakers to examine Allergan's controversial patent deal with a Native American tribe.
In September, Allergan struck an unusual deal with the Saint Regis Mohawk Tribe to transfer...
The health care sector has been one of the better-performing sectors in 2017, bouncing back after being the only sector in the S&P 500 (SPX) to finish last year in the red. So far this year, the S&P Health ...
The White House is eliminating a crucial part of the Affordable Care Act. President Donald Trump wants to immediately stop payments to insurers. The administration said the government cannot legally continue to make payments. Yahoo Finance’s Alexis Christoforous and Rick Newman figure out how this will impact the insurance industry and patients.
After being named Institutional Investor's 2017 number-one biotech analyst, Umer Raffat of Evercore ISI discusses his picks for the biotech and specialty pharma sector.